Idorsia Pharmaceuticals competitive analysis

Explore Idorsia Pharmaceuticals's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Feb 19, 2026
Patent NumberPublication DateTitleTotal Oppositions
Apr 9, 2025Combination Of A 4-Pyrimidinesulfamide Derivative With An Sglt-2 Inhibitor For The Treatment Of Endothelin Related Diseases1
Sep 4, 2024Aprocitentan For Use In The Treatment Of Hypertension And Related Diseases In Combination With Angiotensin Converting Enzyme Inhibitor (Ace) Or Angiotensin Receptor Blocker (Arb)1

Latest PTAB cases involving Idorsia Pharmaceuticals

Discover the latest PTAB cases involving Idorsia Pharmaceuticals, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Idorsia Pharmaceuticals with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Feb 19, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
IDORSIA PHARMACEUTICALS - 2 - -
ELKINGTON AND FIFE95 - - -